Vaccine Contract Manufacturing Market Poised for Steady Growth Through 2032 Amid Rising Immunization Demand – DelveInsight
(Albany, US), September 16, 2026 – DelveInsight’s report “Vaccine Contract Manufacturing Market” delivers an in-depth understanding of the vaccine contract manufacturing market by vaccine type, expression system, end-user, and geography, along with the market trends across North America, Europe, Asia-Pacific, and Rest of the World.
The report provides a detailed analysis of the market drivers, restraints, segment-wise performance, regional dynamics, key players, and recent developmental activities shaping the vaccine contract manufacturing market through the forecast period.
Get a Free sample for the Vaccine Contract Manufacturing Market Size & Share Analysis Report: https://www.delveinsight.com/sample-request/vaccine-contract-manufacturing-market
Some of the key facts of the Vaccine Contract Manufacturing Market Report:
-
The vaccine contract manufacturing market was valued at approximately USD 2,282.36 million in 2024 and is projected to grow at a CAGR of 6.9% from 2025 to 2032, reaching approximately USD 3,905.96 million by 2032.
-
Growth is driven by increasing global vaccine demand, expansion of biobanks, the emergence of new infectious diseases, and rising product development activities across the globe.
-
Inactivated vaccines are estimated to hold a significant revenue share of the market in 2024, owing to their favorable safety profile and established, scalable manufacturing processes.
-
North America is expected to dominate the overall vaccine contract manufacturing market in 2024, supported by advanced healthcare infrastructure, stringent regulatory standards, and high biopharmaceutical R&D investment.
-
Key strategic activities, including facility expansions, partnerships, and regulatory approvals by players such as Sanofi, Moderna, AstraZeneca, BioNTech, and Emergent BioSolutions, continue to shape the competitive landscape.
-
Key Vaccine Contract Manufacturing Companies: Sanofi, Biovac, Emergent BioSolutions Inc., Lonza Group, Catalent Inc., Boehringer Ingelheim BioXcellence, Wockhardt, WuXi Biologics, Moderna, Inc., Syngene International, and others
Vaccine Contract Manufacturing Market Overview
The vaccine contract manufacturing market encompasses the outsourcing of vaccine development and production activities by pharmaceutical and biotechnology companies to specialized Contract Development and Manufacturing Organizations (CDMOs). The market is segmented by vaccine type, including inactivated vaccines, live attenuated vaccines, RNA vaccines, subunit vaccines, and toxoid-based vaccines, and by expression system, spanning bacterial, baculovirus/insect, mammalian, and yeast platforms. End-users include pharmaceutical and biotechnology companies, research institutes and academic laboratories, and others. Rising global vaccine demand driven by widespread immunization programs and an increasing focus on preventative healthcare, along with the growing need for biobanks that supply quality biological samples for vaccine research, continue to support market expansion.
To know in detail about the Vaccine Contract Manufacturing market outlook, drivers, and segmentation, Click here; Vaccine Contract Manufacturing Market Forecast
Vaccine Contract Manufacturing Market Dynamics
The recent surge in vaccine demand, particularly around COVID-19 and RSV, has intensified interest in contract manufacturing as companies and governments work to keep pace with new variants and improved formulations. In August 2024, the U.S. FDA approved and granted emergency use authorization for updated mRNA COVID-19 vaccines incorporating a monovalent component corresponding to the Omicron variant KP.2 strain of SARS-CoV-2, a development expected to boost demand for contract manufacturing capacity.
The emergence of new and re-emerging diseases has further strengthened the market. In May 2022, the World Health Organization reported a sudden monkeypox outbreak across 12 non-endemic member states. The continued emergence of diseases such as Nipah virus, Hantavirus Pulmonary Syndrome, Monkeypox, COVID-19, and Oropouche Virus has increased reliance on contract manufacturers to rapidly scale production capabilities in response to public health threats.
Strategic initiatives such as business expansions, partnerships, and acquisitions among key players are also propelling market growth. In March 2022, Bharat Biotech partnered with Spain-based BIOFABRI to develop, manufacture, and market a new tuberculosis vaccine across more than 70 countries in Southeast Asia and sub-Saharan Africa.
On the restraint side, vaccine production is subject to rigorous and region-specific regulatory requirements, along with stringent storage and transportation conditions such as ultra-cold chain logistics for mRNA vaccines. These cold chain and logistical demands present some obstacles to market growth.
Discover more about the trends shaping the market @ Vaccine Contract Manufacturing Market Trends
Vaccine Contract Manufacturing Market Segment Analysis
Within the vaccine type segment, inactivated vaccines are estimated to hold a significant revenue share of the market in 2024. Because inactivated vaccines contain killed pathogens, they eliminate the risk of causing disease even in immunocompromised individuals, making them well suited for widespread immunization efforts targeting vulnerable populations. Their stability and well-established manufacturing processes also make them easier to store and transport compared with live vaccines, which typically require strict cold chain logistics.
Demand for inactivated vaccines has grown notably for diseases such as influenza, polio, and COVID-19, where multiple booster doses may be required for sustained immunity. This has encouraged pharmaceutical companies to engage contract manufacturers with specialized expertise and scalable production capacity. In June 2024, Sanofi and South Africa-based Biovac announced a local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa, making Biovac the first African producer of IPV on the continent and supporting the Africa CDC’s goal of having 60% of local vaccines produced in Africa by 2040.
The relative simplicity and reduced biosafety risk associated with inactivated vaccine production also allow contract manufacturers to establish facilities more quickly, helping meet global demand and emergency supply needs.
Vaccine Contract Manufacturing Regional Outlook
North America is expected to hold the largest share of the vaccine contract manufacturing market in 2024, supported by advanced healthcare infrastructure, strict regulatory standards, and substantial biopharmaceutical R&D investment. Numerous CDMOs in the region offer advanced technology and large-scale production capacity to meet rising vaccine demand driven by emerging diseases.
According to 2024 data from the Centers for Disease Control and Prevention, childhood vaccination rates by 24 months in North America stood at 80.4% for Diphtheria, Tetanus, and Pertussis, 92.5% for polio, 90.8% for Measles, Mumps, and Rubella, 91.4% for Hepatitis B, and 90.3% for Chickenpox. These sustained vaccination rates highlight ongoing demand for efficient, large-scale vaccine production and reinforce the essential role of contract manufacturing in the region.
Strategic activity continues to strengthen the region’s position. In September 2024, Moderna announced plans to build a new mRNA vaccine manufacturing facility in Quebec, Canada, to expand its production capacity. In August 2024, Emergent BioSolutions received FDA approval of a supplemental Biologics License Application expanding the indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to include prevention of mpox disease in high-risk individuals, a development expected to create additional production demand.
Get a detailed analysis of regional market trends @ Vaccine Contract Manufacturing Market Share
Vaccine Contract Manufacturing Market Key Players
Some of the key market players operating in the vaccine contract manufacturing market include Sanofi, Biovac, Emergent BioSolutions Inc., Lonza Group, Catalent Inc., Boehringer Ingelheim BioXcellence, Wockhardt, WuXi Biologics, Moderna, Inc., Syngene International, Meridian Life Sciences, Eurogentec, IDT Biologika, Serum Institute of India, GlaxoSmithKline (GSK), Soligenix Inc., Curia, Cobra Biologics, BioReliance, Recipharm, Jubilant HollisterStier, and others.
Scope of the Vaccine Contract Manufacturing Market Report
-
Study Period: 2025–2032
-
Base Year: 2024
-
Coverage: North America, Europe, Asia-Pacific, and Rest of the World
-
Vaccine Type: Inactivated Vaccine, Live Attenuated Vaccine, RNA Vaccine, Subunit Vaccines, and Toxoid Based Vaccines
-
Expression System: Bacterial Expression Systems, Baculovirus/Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems
-
End-User: Pharmaceutical & Biotechnology Companies, Research Institutes & Academic Laboratories, and Others
-
Key Vaccine Contract Manufacturing Companies: Sanofi, Biovac, Emergent BioSolutions Inc., Lonza Group, Catalent Inc., Boehringer Ingelheim BioXcellence, Wockhardt, WuXi Biologics, Moderna, Inc., Syngene International, and others
To know more about vaccine contract manufacturing companies and market opportunities, visit @ Vaccine Contract Manufacturing Market Analysis and Forecast
Table of Content
-
Vaccine Contract Manufacturing Market Report Introduction
-
Vaccine Contract Manufacturing Market Executive Summary
-
Competitive Landscape
-
Regulatory Analysis
-
Vaccine Contract Manufacturing Market Key Factors Analysis
-
Vaccine Contract Manufacturing Market Porter’s Five Forces Analysis
-
Vaccine Contract Manufacturing Market Assessment
-
Vaccine Contract Manufacturing Market Company and Product Profiles
-
KOL Views
-
Project Approach
-
About DelveInsight
-
Disclaimer & Contact Us
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Abhishek kumar
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/vaccine-contract-manufacturing-market
